Company intelligence / Profile preview

FlyPharma

Tokushima, Tokushima, Japan

Ownership: Private
Development stage: Other

Overview

Delta-Fly Pharma uses a unique "module technology" to combine active ingredients from existing drugs to develop gentler anticancer agents with improved safety and efficacy profiles. It has six pipeline projects focused on oncology, advancing through clinical stages, but exact recent results are not publicly detailed in search results[3][4].

Therapeutic areas: Oncology
Modalities: Small moleculeCombination therapy
Industry: Biotech

Partnerships

Pharmaceutical companies via licensing agreements (specific names not provided)

Beyond the preview

Go deeper on FlyPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FlyPharma.

Explore the full profile